AGTR1
AGTR1 is a G protein-coupled receptor that mediates the primary cardiovascular and fibrotic effects of angiotensin II. Chronic activation of AGTR1 accelerates vascular aging and drives hypertension, making it a major pharmacological target for lifespan extension.
Key Takeaways
- •AGTR1 is a master regulator of blood pressure and fluid balance, mediating the effects of Angiotensin II.
- •Chronic activation drives vascular aging, hypertension, and systemic fibrosis.
- •It is the primary target for Angiotensin Receptor Blockers (ARBs), such as Losartan.
- •Inhibiting AGTR1 has been shown to extend lifespan in multiple animal models by reducing oxidative stress.
Basic Information
- Gene Symbol
- AGTR1
- Full Name
- Angiotensin II Receptor Type 1
- Also Known As
- AT1RAT1AGTR1A
- Location
- 3q24
- Protein Type
- G Protein-Coupled Receptor
- Protein Family
- Angiotensin Receptor Family
Related Isoforms
Key SNPs
The A1166C variant. Associated with altered receptor expression and increased responsiveness to Angiotensin II, leading to higher hypertension risk.
Overview
The AGTR1 gene encodes the Angiotensin II Receptor Type 1 (AT1R), a G protein-coupled receptor that acts as the primary effector for the renin-angiotensin-aldosterone system (RAAS). When the octapeptide Angiotensin II binds to AGTR1, it initiates a powerful vasoconstrictive and pro-inflammatory response essential for maintaining acute blood pressure but deleterious when chronically overactive.
AGTR1 signaling is complex, primarily coupling to Gq/11 proteins to increase intracellular calcium, but also signaling via beta-arrestins to activate MAPK cascades. Beyond its role in vascular tone, AGTR1 is a critical driver of age-related cardiovascular and renal decline, promoting cellular senescence and tissue fibrosis through the induction of oxidative stress.
Conceptual Model
A simplified mental model for the pathway:
AGTR1 is the cellular endpoint of the RAAS pathway; it translates hormonal signals into physical arterial pressure.
Core Health Impacts
- • Blood pressure: Directly increases systemic blood pressure via potent vasoconstriction.
- • Sodium retention: Promotes sodium and water retention in the kidneys via aldosterone.
- • Tissue fibrosis: Drives the pathological stiffening of the heart, kidneys, and blood vessels.
- • Oxidative stress: Activates NADPH oxidases to increase production of reactive oxygen species (ROS).
Protein Domains
7-Transmembrane Domain
The core GPCR structure consisting of seven alpha-helices that span the cell membrane.
Extracellular Loops
Form the binding pocket for the Angiotensin II peptide ligand.
Cytoplasmic Tail
Contains phosphorylation sites for GRKs and binding sites for beta-arrestins and G-proteins.
Upstream Regulators
Angiotensin II Activator
The primary peptide ligand; levels are controlled by Renin and ACE activity.
Mechanical Stretch Activator
Can activate the receptor independently of the ligand in certain vascular contexts.
Sympathetic Tone Activator
High sympathetic activity drives the RAAS cascade to provide more Angiotensin II.
ARBs (Losartan) Inhibitor
Competitive antagonists that physically block the receptor binding site.
Downstream Targets
Phospholipase C (PLC) Activates
Couples to Gq to generate IP3 and DAG, raising intracellular calcium.
Protein Kinase C (PKC) Activates
Mediates long-term effects on cell growth, remodeling, and inflammation.
Aldosterone Activates
Indirect target; AGTR1 activation in the adrenal gland stimulates aldosterone release.
NADPH Oxidase Activates
The primary source of AGTR1-induced oxidative stress in the vascular wall.
Role in Aging
AGTR1 is a central "Aging Gene." Chronic over-activity of this receptor is one of the primary drivers of the cardiovascular hallmarks of aging.
Vascular Senescence
Chronic AGTR1 signaling induces DNA damage and permanent cell cycle arrest in endothelial cells.
Systemic Fibrosis
It promotes the transition of healthy tissue into non-functional scar tissue in the heart and kidneys as the body ages.
Longevity Extension
Mice lacking AGTR1 (knockout) or treated with ARBs consistently show extended lifespans compared to controls.
Mitochondrial Decay
AGTR1-induced ROS production damages mitochondria, leading to a decline in cellular energy efficiency over time.
Disorders & Diseases
Essential Hypertension
Primary driver of high blood pressure via chronic vasoconstriction and volume expansion.
Heart Failure
Maladaptive AGTR1 signaling drives the fibrosis and remodeling that leads to pump failure.
Diabetic Nephropathy
High intra-renal AGTR1 activity damages the glomerular filter, leading to chronic kidney disease.
Aortic Aneurysm
Excessive AGTR1 signaling is implicated in the weakening of the aortic wall in syndromes like Marfan.
Interventions
Supplements
Counteracts the sodium-retaining effects of the AGTR1/Aldosterone axis.
Acts as a natural calcium channel blocker, mildly opposing the downstream effects of AGTR1.
Known to downregulate the Renin gene, thereby reducing the total ligand pool for AGTR1.
Lifestyle
The most direct way to lower the homeostatic requirement for AGTR1-mediated pressure control.
Reduces sympathetic drive and improves the protective, opposing AGTR2/MAS pathways.
Lowers chronic cortisol and sympathetic activity that otherwise keeps the RAAS system "hot."
Medicines
Directly block AGTR1; preferred for many due to lack of the "ACE cough" side effect.
Indirectly reduce AGTR1 activation by preventing the formation of Angiotensin II.
A unique ARB that also acts as a partial PPARγ agonist, providing metabolic benefits.
Lab Tests & Biomarkers
Clinical Markers
The definitive clinical readout of the integrated activity of the AGTR1 pathway.
Used to classify the degree of RAAS activation and guide ARB therapy.
Hormonal Interactions
Angiotensin II Primary Agonist
The mandatory key that turns on the AGTR1 receptor.
Aldosterone Downstream Effector
Released in response to AGTR1 to manage long-term fluid volume.
Atrial Natriuretic Peptide Antagonist
The heart’s own hormone that counteracts AGTR1 effects to lower pressure.
Deep Dive
Network Diagrams
AGTR1 Signaling Cascade
RAAS Balance: AGTR1 vs. Protective Arms
Activation Mechanics: The Gq and Arrestin Relay
AGTR1 is an atypical GPCR because its signaling results in both acute physical changes and long-term structural remodeling through divergent pathways.
Acute Vasoconstriction (Gq Pathway): Upon Angiotensin II binding, AGTR1 couples to Gq/11 proteins. This activates Phospholipase C (PLC), which generates IP3. IP3 triggers the rapid release of calcium from the endoplasmic reticulum. In vascular smooth muscle cells, this calcium spike causes immediate contraction, narrowing the vessel and raising blood pressure.
Long-term Remodeling (Arrestin Pathway): AGTR1 also signals via beta-arrestins, which act as scaffolds for MAPK cascades. This pathway is independent of the G-protein “spark” and is responsible for the growth-promoting and fibrotic effects of the receptor. It is this pathway that ARBs are particularly effective at dampening, preventing the thickening of the heart and the stiffening of the arteries.
The Balancing Act: AGTR1 vs. AGTR2 and MAS
The renin-angiotensin system has a “dark side” (AGTR1) and a “light side” (AGTR2 and the MAS receptor).
While AGTR1 drives vasoconstriction, inflammation, and aging, the AGTR2 receptor and the MAS receptor (activated by Angiotensin 1-7) do the exact opposite: they promote vasodilation, reduce inflammation, and protect the brain and heart.
In a youthful state, these pathways are in balance. In the aging process, the protective ACE2/MAS arm often declines, while the AGTR1 arm becomes dominant. This shift is a fundamental driver of “inflammaging.” Targeted interventions like Telmisartan are prized because they selectively block the harmful AGTR1 while leaving the protective pathways intact or even indirectly enhancing them.
AGTR1 and Mitochondrial Life-Extension
The link between AGTR1 and longevity was cemented by the discovery that mice lacking the receptor live significantly longer. The mechanism appears to be mitochondrial.
Chronic AGTR1 activation stimulates the production of reactive oxygen species (ROS). These ROS damage the mitochondria within vascular and renal cells. By blocking AGTR1, you reduce this chronic oxidative stress, preserving mitochondrial function and preventing the transition of cells into a senescent state. This makes ARBs some of the most well-validated “geroprotective” medicines currently in clinical use.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
The first major study linking the rs5186 variant to the genetic risk of hypertension.
Demonstrated that mice lacking the Agtr1a gene live 26% longer than wild-type controls.